Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer

Cancer

Volumn 122, Issue 3, 2016, Pages 447-455

  Laviana, Aaron A ^a   Ilg, Annette M ^a   Veruttipong, Darlene ^a   Tan, Hung Jui ^a,b   Burke, Michael A ^c   Niedzwiecki, Douglas R ^c   Kupelian, Patrick A ^a   King, Chris R ^a   Steinberg, Michael L ^a   Kundavaram, Chandan R ^a   Kamrava, Mitchell ^a   Kaplan, Alan L ^a   Moriarity, Andrew K ^a   Hsu, William ^a   Margolis, Daniel J A ^a   Hu, Jim C ^d   Saigal, Christopher S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

active surveillance; brachytherapy; cost analysis; prostate neoplasms; radical prostatectomy; radiotherapy; value based purchasing

Indexed keywords

ARTICLE; BRACHYTHERAPY; COST CONTROL; CRYOTHERAPY; DISEASE SURVEILLANCE; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HOSPITAL COST; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; ROBOT ASSISTED SURGERY; ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY; STEREOTACTIC BODY RADIATION THERAPY; TIME DRIVEN ACTIVITY BASED COSTING; TRANSRECTAL ULTRASONOGRAPHY; AGED; COST BENEFIT ANALYSIS; ECONOMICS; FEASIBILITY STUDY; HEALTH SURVEY; LAPAROSCOPY; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIOSURGERY; RISK ASSESSMENT; RISK FACTOR; ROBOTIC SURGICAL PROCEDURE; UNITED STATES; VERY ELDERLY; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COST-BENEFIT ANALYSIS; FEASIBILITY STUDIES; HEALTH CARE COSTS; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; RISK FACTORS; ROBOTIC SURGICAL PROCEDURES; UNITED STATES; WATCHFUL WAITING;

EID: 84949239170     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29743     Document Type: Article

References (44)

1. Siegal R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Etzioni R, Gulati R, Tsodikov A, et al., The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012; 118: 5955-5963.
3. Mariotto AB, Yabroff KR, Shao Y, et al., Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
4. Thompson I, Thrasher JB, Aus G, et al., Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131.
5. Lotan Y,. Controlling health care costs for prostate cancer. Eur Urol. 2013; 64: 17-18.
6. O'Leary MP, Baum NH, Blizzard R, et al,; Health Policy Survey and Research Committee. 2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol. 2002; 168: 649-652.
7. Kaplan RS, Porter ME,. How to solve the cost crisis in health care. Harv Bus Rev. 2011; 89: 46-52.
8. Porter ME, Lee TH,. The strategy that will fix health care. Harv Bus Rev. 2013; 91: 1-19.
9. Pate SC, Uhlman MA, Rosenthal JA, et al., Variations in the open market costs for prostate cancer surgery: a survey of US hospitals. Urology. 2014; 83: 626-630.
10. Porter ME,. What is value in health care. N Engl J Med. 2010; 363: 2477-2981.
11. Stout DE, Propri JM,. Implementing time-driven activity-based costing at a medium-sized electronics company. Manag Account Q. 2011; 12: 1-11.
12. Kaplan RS,. Improving value with TDABC. Time-driven activity-based costing presents significant opportunities to enhance quality of care and outcomes while reducing costs- and provides a foundation for value-based payment. Healthc Financ Manage. 2014; 68: 76-83.
13. Kaplan RS, Anderson SR,. Time-driven activity-based costing. Harv Bus Rev. 2004; 82: 131-138.
14. McLaughlin N, Burke MA, Setlur NP, et al., Time-driven activity-based costing: a driver for provider engagement in costing activities and redesign initiatives. Neurosurg Focus. 2014; 37: E3.
15. McLaughlin N, Upadhyay P, Buxey F, Martin NA,. Value-based neurosurgery: measuring and reducing the cost of microvascular decompression surgery. J Neurosurg. 2014; 121: 700-709.
16. Wilt TJ, Brawer MK, Jones KM, et al., Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
17. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
18. Kaplan AL, Agarwal, Setlur NP, et al., Measuring the cost of care in benign prostatic hypertrophy using time driven activity-based costing (TDABC). Healthc (Amst). 2015; 3: 43-48.
19. Ubel PA, Asch DA,. Creating value in health by understanding and overcoming resistance to de-innovation. Health Aff (Millwood). 2015; 34: 239-244.
20. Daskivich TJ, Fan KH, Koyama T, et al., Effect of age, tumorrisk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013; 158: 709-717.
21. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR,. Comparative risk-adjusted mortality outcomes following primary surgery, radiation therapy, or androgen deprivation therapy for localized prostate cancer. Cancer. 2010; 116: 5226-5234.
22. Waago-Hansen C,. How time-driven activity-based costing (TDABC) enables better use of existing resources in order to improve return on investment (ROI) in modern healthcare and hence facilitates a sustainable healthcare system. the Health. 2014; 5: 3-8.
23. Neuner JM, See WA, Pezzin LE, et al., The association of robotic surgical technology and hospital prostatectomy volumes: increasing market share through the adoption of technology. Cancer. 2012; 118: 371-377.
24. Bolenz C, Gupta A, Hotze T, et al., Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol. 2010; 57: 453-458.
25. Mouraviev V, Nosnik I, Sun L, et al., Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007; 69: 311-314.
26. Yu HY, Hevelone ND, Lipsitz SR, et al., Use, costs and comparative effectiveness of robotic assisted, laparoscopic, and open urological surgery. J Urol. 2012; 187: 1392-1398.
27. Lau HK, Chen TH, Liou CM, et al., Retrospective analysis of surgery postponed or cancelled in the operating room. J Clin Anesth. 2010; 22: 237-240.
28. Park KW, Dickerson C,. Can efficient supply management in the operating room save millions? Curr Opin Anaesthesiol. 2009; 22: 242-248.
29. Carter SC, Lipsitz S, Shih YC, Nguyen PL, Trinh QD, Hu JC,. Population-based determinants of radical prostatectomy operative time. BJU Int. 2014; 113: E112-E118.
30. Proctor LD, Davenport DL, Bernard AC, Zwischenberger JB,. General surgical operative duration is associated with increased risk-adjusted infectious complication rates and length of hospital stay. J Am Coll Surg. 2010; 210: 60-65.
31. Yu JB, Cramer JD, Herrin J, et al., Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol. 2014; 32: 1195-1201.
32. Sher DJ, Parikh RB, Mays-Jackson S, Punglia RS,. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol. 2014; 37: 215-221.
33. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS,. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol. 2010; 33: 481-488.
34. Shah C, Lanni TB, Ghilezan MI, et al., Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy. 2012; 11: 441-445.
35. Pinto PA, Chung PH, Rastinehad AR, et al., Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011; 186: 1281-1285.
36. de Rooij M, Crienen S, Witjes JA, et al., Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosis prostate cancer: a modeling study from a health care perspective. Eur Urol. 2014; 66: 430-436.
37. Sonn GA, Chang E, Natarajan S, et al., Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014; 65: 809-815.
38. Marks L, Young S, Natarajan S,. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013; 23: 43-50.
39. Centers for Medicare and Medicaid Services. Outpatient charge data CY 2013. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Outpatient2013.html. Accessed June 1, 2015.
40. Russell LB,. Completing costs: patients' time. Med Care. 2009; 47 (7 suppl 1): S89-S93.
41. Bastian PJ, Boorjian SA, Bossi A, et al., High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012; 61: 1096-1106.
42. Musunuru HB, Klotz L, Vespirini D, et al., Cautionary tale of active surveillance in intermediate-risk patients: overall and cause-specific survival in the Sunnybrook experience [abstract]. J Clin Oncol. 2015; 33 (suppl 7): 163.
43. Shappley WV III, Kenfield SA, Kasperzyk JL, et al., Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009; 27: 4980-4985.
44. Bokhorst LP, Alberts AR, Rannikko A, et al., Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol. In press. [Epub ahead of print]